Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial.

Kjøller E, Hilden J, Winkel P, Galatius S, Frandsen NJ, Jensen GB, Fischer Hansen J, Kastrup J, Jespersen CM, Hildebrandt P, Kolmos HJ, Gluud C; CLARICOR Trial Group.

Am Heart J. 2014 Aug;168(2):197-204.e1-4. doi: 10.1016/j.ahj.2013.12.032. Epub 2014 May 4.

PMID:
25066559
2.

Safe application of a restrictive transfusion protocol in moderate-risk patients undergoing cardiac operations.

Song HK, von Heymann C, Jespersen CM, Karkouti K, Korte W, Levy JH, Ranucci M, Saugstrup T, Sellke FW.

Ann Thorac Surg. 2014 May;97(5):1630-5. doi: 10.1016/j.athoracsur.2013.12.025. Epub 2014 Mar 19.

PMID:
24655469
3.

Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial.

Karkouti K, von Heymann C, Jespersen CM, Korte W, Levy JH, Ranucci M, Sellke FW, Song HK.

J Thorac Cardiovasc Surg. 2013 Oct;146(4):927-39. doi: 10.1016/j.jtcvs.2013.04.044. Epub 2013 Jun 29.

4.

Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease.

Kjoller E, Hilden J, Winkel P, Frandsen NJ, Galatius S, Jensen G, Kastrup J, Hansen JF, Kolmos HJ, Jespersen CM, Hildebrandt P, Gluud C; CLARICOR Trial Group.

J Clin Epidemiol. 2012 Apr;65(4):444-53. doi: 10.1016/j.jclinepi.2011.09.011. Epub 2012 Jan 17.

PMID:
22257841
5.

Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?

Winkel P, Hilden J, Fischer Hansen J, Hildebrandt P, Kastrup J, Kolmos HJ, Kjøller E, Jespersen CM, Gluud C, Jensen GB; CLARICOR Trial Group.

Cardiology. 2011;118(1):63-7. doi: 10.1159/000324533. Epub 2011 Mar 26.

PMID:
21447948
6.

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.

Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group.

Scand J Clin Lab Invest. 2011 Feb;71(1):52-62. doi: 10.3109/00365513.2010.538081. Epub 2010 Nov 25.

PMID:
21108561
7.

Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial.

Hilden J, Lind I, Kolmos HJ, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Jensen GB, Kastrup J, Kjøller E, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group.

Diagn Microbiol Infect Dis. 2010 Apr;66(4):385-92. doi: 10.1016/j.diagmicrobio.2009.11.011.

PMID:
20226329
8.

Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease.

Jensen GB, Hilden J, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM, Gluud C; CLARICOR Trial Group.

J Cardiovasc Pharmacol. 2010 Feb;55(2):123-8. doi: 10.1097/FJC.0b013e3181c87e37.

PMID:
19920766
9.

Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report.

Levy JH, Gill R, Nussmeier NA, Olsen PS, Andersen HF, Booth FV, Jespersen CM.

Thromb Haemost. 2009 Oct;102(4):765-71. doi: 10.1160/TH08-12-0826.

PMID:
19806264
10.

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.

Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjøller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; CLARICOR Trial Group.

Eur Heart J. 2009 May;30(9):1066-72. doi: 10.1093/eurheartj/ehp049. Epub 2009 Mar 6.

PMID:
19270316
11.

Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease.

Gluud C, Als-Nielsen B, Damgaard M, Fischer Hansen J, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Jespersen CM; CLARICOR Trial Group.

Cardiology. 2008;111(4):280-7. doi: 10.1159/000128994. Epub 2008 May 2.

12.

Myocardial stress in patients with acute cerebrovascular events.

Jespersen CM, Fischer Hansen J.

Cardiology. 2008;110(2):123-8. Epub 2007 Oct 31. Review.

PMID:
17975312
13.

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial.

Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Gluud C; CLARICOR Trial Group.

BMJ. 2006 Jan 7;332(7532):22-7. Epub 2005 Dec 8. Erratum in: BMJ. 2006 Jan 21;332(7534):151.

14.

[The small blue pills].

Jespersen CM.

Ugeskr Laeger. 2002 Sep 2;164(36):4203. Danish. No abstract available.

PMID:
12362843

Supplemental Content

Loading ...
Support Center